Neuropeptides and Cognitive Function
The brain's capacity for learning, memory, attention, and executive function depends on the health and plasticity of its neural networks. Synaptic connections must be formed, strengthened, pruned, and maintained throughout life — processes governed by neurotrophic factors, neurotransmitter balance, and cellular energy metabolism. Research peptides that modulate these processes have emerged as important tools for studying cognitive biology.
Three peptides — Semax, Selank, and Dihexa — represent the current frontiers of cognitive peptide research. Each acts through distinct mechanisms, and together they illustrate the range of molecular strategies available for studying brain function.
Semax: The BDNF-Upregulating Neuropeptide
Development and Clinical Background
Semax was developed at the Institute of Molecular Genetics, Russian Academy of Sciences, as a synthetic analog of ACTH(4-10) — the behaviorally active fragment of adrenocorticotropic hormone. The heptapeptide sequence (Met-Glu-His-Phe-Pro-Gly-Pro) includes a C-terminal Pro-Gly-Pro extension that protects against enzymatic degradation. Semax has been approved for clinical use in Russia since 1994 for cognitive disorders and cerebrovascular conditions.
Core Mechanisms
BDNF upregulation: Brain-derived neurotrophic factor is the primary neurotrophin supporting synaptic plasticity, long-term potentiation (LTP), and memory consolidation. Dolotov et al. (2006) demonstrated that Semax significantly increases BDNF expression in the hippocampus and prefrontal cortex — the brain regions most critical for declarative memory and executive function.
NGF and GDNF modulation: Beyond BDNF, Semax affects nerve growth factor and glial cell line-derived neurotrophic factor expression (Shadrina et al., 2010), supporting both neuronal survival and the glial cells that maintain the neural microenvironment.
Dopaminergic modulation: Semax influences dopamine and serotonin turnover in the basal ganglia and limbic system (Eremin et al., 2005). Dopamine is central to motivation, attention, and working memory — functions that depend on optimal prefrontal cortex dopamine levels.
Broad gene expression effects: Agapova et al. (2007) used microarray analysis to show Semax modulates genes involved in immune function, vascular biology, and neuroprotection — suggesting neuroprotective activity beyond direct neurotrophic signaling.
Cognitive Research Findings
Clinical studies in healthy human volunteers demonstrated Semax's effects on attention, short-term memory, and cognitive flexibility following intranasal administration (Kaplan et al., 1996). In models of cerebral ischemia, Semax reduced neurological deficit scores and infarct volume (Gusev et al., 1997), supporting neuroprotective activity under conditions of metabolic stress.
Selank: The Anxiolytic Neuropeptide
Development and Clinical Background
Selank was developed at the same institute as Semax, as a synthetic analog of the immunomodulatory peptide tuftsin (Thr-Lys-Pro-Arg), extended with the Pro-Gly-Pro stabilizing sequence. It was approved for clinical use in Russia in 2009 for generalized anxiety disorder and neurasthenia.
Core Mechanisms
GABA-A modulation: Selank enhances GABAergic neurotransmission at GABA-A receptors without binding to the benzodiazepine site (Seredenin et al., 2001). This mechanism produces anxiolytic effects without sedation, tolerance development, or cognitive impairment — common limitations of classical benzodiazepines.
Enkephalin stabilization: Selank inhibits enzymes that degrade endogenous enkephalins, increasing their available concentration (Zozulya et al., 2001). Enkephalins modulate pain, emotional tone, and stress response through the endogenous opioid system.
Serotonergic influence: Research documents Selank's effects on serotonin metabolism and 5-HT receptor binding in limbic structures, contributing to mood regulation through a mechanism distinct from SSRIs.
Immune-brain axis: As a tuftsin derivative, Selank retains immunomodulatory properties. Uchakina et al. (2008) demonstrated effects on cytokine balance, particularly IL-6, which has implications for neuroinflammation-mediated cognitive impairment.
Cognitive Relevance
While Selank is primarily studied as an anxiolytic, anxiety and cognition are intimately linked. The Yerkes-Dodson law describes an inverted-U relationship between arousal and performance — moderate anxiety enhances cognitive function, but excessive anxiety impairs it. Selank's ability to modulate anxiety without sedation positions it as a cognitive optimization tool through emotional regulation.
Dihexa: The Synaptogenic Peptide
Development
Dihexa (N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide) was developed by researchers at Washington State University as a stable, orally active derivative of angiotensin IV. It represents a novel approach to cognitive enhancement through synaptogenesis — the formation of new synaptic connections.
Core Mechanisms
HGF/c-Met potentiation: Dihexa's primary mechanism involves stabilizing the interaction between hepatocyte growth factor (HGF) and its receptor c-Met. McCoy et al. (2013) demonstrated that Dihexa is approximately 10 million times more potent than BDNF at promoting new synapse formation in hippocampal neuron cultures.
Synaptogenesis: By enhancing HGF/c-Met signaling, Dihexa promotes the formation of new dendritic spines and functional synapses (Benoist et al., 2014). This expands the neural substrate available for information processing and memory encoding.
Cognitive rescue: In scopolamine-impaired animal models, Dihexa restored cognitive performance on spatial learning and memory tasks (McCoy et al., 2013). This suggests activity even in contexts where cholinergic function is compromised.
Significance
Dihexa's HGF/c-Met mechanism is distinct from the BDNF/TrkB pathway targeted by most neurotrophic compounds. While BDNF primarily strengthens existing synapses (LTP), HGF/c-Met signaling promotes the creation of new ones. This mechanistic distinction makes Dihexa a complementary tool to BDNF-enhancing peptides like Semax.
Comparative Analysis
- Primary target: Semax → BDNF/TrkB; Selank → GABA-A/enkephalins; Dihexa → HGF/c-Met
- Cognitive domain: Semax → memory and attention; Selank → emotional regulation and stress resilience; Dihexa → synaptic density and network capacity
- Time course: Selank → hours (anxiolysis); Semax → days-weeks (neurotrophic); Dihexa → weeks (synaptogenesis)
- Route: Semax and Selank → primarily intranasal; Dihexa → oral bioavailability demonstrated
This article is for educational and informational purposes only. BeaCapra supplies research peptides for laboratory and research use. Nothing in this article constitutes medical advice.